Glenmark molecule to enter human trials in Netherlands

18 Feb 2011 Evaluate

Glenmark Pharmaceuticals has filed an application in Netherlands for human trials on its molecule ‘GRC 17536’, which aims to treat pain and respiratory disorders. The company has completed animal trials on its novel chemical entity (NCE) GRC 17536 and has filed the Phase I application for first-in-man trial in Netherlands, Glenmark Pharmaceuticals.

The total market for asthma and chronic lung disease is about $30 billion and for osteoarthritis and neuropathic pain, it is nearly $10 billion. There is a huge unmet medical need in both therapeutic areas globally. crackcrack

Glenmark Pharma Share Price

2033.00 7.60 (0.38%)
02-Jan-2026 09:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.00
Dr. Reddys Lab 1239.95
Cipla 1501.60
Zydus Lifesciences 913.50
Lupin 2104.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×